Cargando…
Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients
Atopic dermatitis (AD) can have a significantly negative impact on quality of life (QoL). The impact of coronavirus disease 2019 (COVID-19) on the AD population is not yet well established. The study comprised 195 patients with diagnosed AD who were asked about their cognitive and preventive behavio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835216/ https://www.ncbi.nlm.nih.gov/pubmed/35162757 http://dx.doi.org/10.3390/ijerph19031734 |
_version_ | 1784649374839603200 |
---|---|
author | Sieniawska, Joanna Lesiak, Aleksandra Ciążyński, Karol Narbutt, Joanna Ciążyńska, Magdalena |
author_facet | Sieniawska, Joanna Lesiak, Aleksandra Ciążyński, Karol Narbutt, Joanna Ciążyńska, Magdalena |
author_sort | Sieniawska, Joanna |
collection | PubMed |
description | Atopic dermatitis (AD) can have a significantly negative impact on quality of life (QoL). The impact of coronavirus disease 2019 (COVID-19) on the AD population is not yet well established. The study comprised 195 patients with diagnosed AD who were asked about their cognitive and preventive behaviors regarding COVID-19 and the accessibility of medical support, including online consultations. Moreover, the patients responded to the self-reported Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale (HADS). Most of the patients were worried about being infected with COVID-19. Most of the patients believed that people suffering from skin disease were more prone to be infected with COVID-19 compared with the general population. Most the patients negatively assessed the availability of dermatological treatment during the pandemic. Furthermore, 66.1% of the patients declared using telemedicine. Nearly 50% of patients were discontented with telemedicine, and 1/3 of the patients did not mind the use of telemedicine. AD during the COVID-19 pandemic was associated with a lower overall health rating and life satisfaction and impaired QoL related to mental health in a Polish population. These results provide original information that can be applied in dermatologic patient screenings to evaluate the state of depression and anxiety during the epidemic period. |
format | Online Article Text |
id | pubmed-8835216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88352162022-02-12 Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients Sieniawska, Joanna Lesiak, Aleksandra Ciążyński, Karol Narbutt, Joanna Ciążyńska, Magdalena Int J Environ Res Public Health Article Atopic dermatitis (AD) can have a significantly negative impact on quality of life (QoL). The impact of coronavirus disease 2019 (COVID-19) on the AD population is not yet well established. The study comprised 195 patients with diagnosed AD who were asked about their cognitive and preventive behaviors regarding COVID-19 and the accessibility of medical support, including online consultations. Moreover, the patients responded to the self-reported Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale (HADS). Most of the patients were worried about being infected with COVID-19. Most of the patients believed that people suffering from skin disease were more prone to be infected with COVID-19 compared with the general population. Most the patients negatively assessed the availability of dermatological treatment during the pandemic. Furthermore, 66.1% of the patients declared using telemedicine. Nearly 50% of patients were discontented with telemedicine, and 1/3 of the patients did not mind the use of telemedicine. AD during the COVID-19 pandemic was associated with a lower overall health rating and life satisfaction and impaired QoL related to mental health in a Polish population. These results provide original information that can be applied in dermatologic patient screenings to evaluate the state of depression and anxiety during the epidemic period. MDPI 2022-02-02 /pmc/articles/PMC8835216/ /pubmed/35162757 http://dx.doi.org/10.3390/ijerph19031734 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sieniawska, Joanna Lesiak, Aleksandra Ciążyński, Karol Narbutt, Joanna Ciążyńska, Magdalena Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients |
title | Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients |
title_full | Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients |
title_fullStr | Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients |
title_full_unstemmed | Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients |
title_short | Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients |
title_sort | impact of the covid-19 pandemic on atopic dermatitis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835216/ https://www.ncbi.nlm.nih.gov/pubmed/35162757 http://dx.doi.org/10.3390/ijerph19031734 |
work_keys_str_mv | AT sieniawskajoanna impactofthecovid19pandemiconatopicdermatitispatients AT lesiakaleksandra impactofthecovid19pandemiconatopicdermatitispatients AT ciazynskikarol impactofthecovid19pandemiconatopicdermatitispatients AT narbuttjoanna impactofthecovid19pandemiconatopicdermatitispatients AT ciazynskamagdalena impactofthecovid19pandemiconatopicdermatitispatients |